Current Report · Items 8.01 · 8-K

Oncolytics Biotech, Inc.

ONCYNASDAQEQUITYCurrent

Other Events

Filed Sep 10, 2026Accepted Sep 10, 2026, 8:17 AM EDTCIK 1129928Accession 0001129928-26-000055

Company context

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically “cold” tumors “hot” through the activation of innate and adaptive immune responses.

Current securities

ONCYNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 8.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events

Item 8.01. Other Events. On September 10, 2026, Oncolytics Biotech Inc. (the “Company”) issued a press release announcing results from a preclinical study evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. The information set forth in this Item 8.01 and in Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

Get the free weekly BCS email.